Log in
NASDAQ:INBX

Checkmate Pharmaceuticals Stock Forecast, Price & News

$17.77
+0.42 (+2.42 %)
(As of 09/29/2020 12:00 AM ET)
Add
Compare
Today's Range
$17.29
Now: $17.77
$18.20
50-Day Range N/A
52-Week Range
$15.76
Now: $17.77
$26.98
Volume20,580 shs
Average Volume109,660 shs
Market Capitalization$651.45 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a multivalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcomas; and INBRX-105, an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc-fusion protein-based therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency; and INBRX-103, a mAb in Phase 1 clinical trials that targets cluster of differentiation 47. Its preclinical programs include INBRX-106, a sdAb-based hexavalent agonist of OX40 for a range of oncology indications; and INBRX-111, a multi-functional antibody that targets Pseudomonas aeruginosa. The company was founded in 2010 and is headquartered in La Jolla, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.30 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INBX
CUSIPN/A
CIKN/A
Phone858-795-4220

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees75
Market Cap$651.45 million
Next Earnings DateN/A
OptionableNot Optionable
$17.77
+0.42 (+2.42 %)
(As of 09/29/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INBX News and Ratings via Email

Sign-up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Checkmate Pharmaceuticals (NASDAQ:INBX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Checkmate Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Checkmate Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Checkmate Pharmaceuticals
.

What price target have analysts set for INBX?

3 equities research analysts have issued twelve-month price objectives for Checkmate Pharmaceuticals' stock. Their forecasts range from $26.00 to $30.00. On average, they anticipate Checkmate Pharmaceuticals' share price to reach $28.67 in the next year. This suggests a possible upside of 61.3% from the stock's current price.
View analysts' price targets for Checkmate Pharmaceuticals
.

Who are some of Checkmate Pharmaceuticals' key competitors?

What other stocks do shareholders of Checkmate Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Checkmate Pharmaceuticals investors own include Trevena (TRVN), Advanced Micro Devices (AMD), Abbott Laboratories (ABT), Ampio Pharmaceuticals (AMPE), Activision Blizzard (ATVI), Boxlight (BOXL), BioXcel Therapeutics (BTAI), Daqo New Energy (DQ), Genocea Biosciences (GNCA) and Horizon Therapeutics (HZNP).

Who are Checkmate Pharmaceuticals' key executives?

Checkmate Pharmaceuticals' management team includes the following people:
  • Mr. Mark Paul Lappe, Founder, Chairman, Pres & CEO (Age 53)
  • Dr. Brendan P. Eckelman, Founder, Chief Scientific Officer, Exec. VP of Corp. Strategy & Director (Age 41)
  • Mr. Quinn L. Deveraux, Founder & Exec. VP of Early Research
  • Ms. Kelly D. Deck B.S., C.P.A., M.S., Chief Financial Officer (Age 40)
  • Ms. Leah Pollema, VP & Gen. Counsel

When did Checkmate Pharmaceuticals IPO?

(INBX) raised $102 million in an initial public offering (IPO) on Wednesday, August 19th 2020. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse acted as the underwriters for the IPO and LifeSci Capital was co-manager.

What is Checkmate Pharmaceuticals' stock symbol?

Checkmate Pharmaceuticals trades on the NASDAQ under the ticker symbol "INBX."

How do I buy shares of Checkmate Pharmaceuticals?

Shares of INBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Checkmate Pharmaceuticals' stock price today?

One share of INBX stock can currently be purchased for approximately $17.77.

How big of a company is Checkmate Pharmaceuticals?

Checkmate Pharmaceuticals has a market capitalization of $651.45 million. Checkmate Pharmaceuticals employs 75 workers across the globe.

What is Checkmate Pharmaceuticals' official website?

The official website for Checkmate Pharmaceuticals is www.inhibrx.com.

How can I contact Checkmate Pharmaceuticals?

Checkmate Pharmaceuticals' mailing address is 11025 N. TORREY PINES ROAD SUITE 200, LA JOLLA CA, 92037. The company can be reached via phone at 858-795-4220 or via email at [email protected]

This page was last updated on 9/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.